Lyme Diagnostics Opportunity to engage InBios on expanding their Lyme Detect Multiplex ELISA, leveraging their ML-assisted analysis platform to position a broader Lyme disease diagnostic portfolio for clinics and reference labs.

Strongy Population Security around parasitic infection testing presents a cross-sell path for Strongy Detect IgG ELISA, with rapid results under 75 minutes, targeting clinical laboratories and high-complexity labs seeking faster turnaround.

POC & AI Align with InBios’ interest in automated software and machine-learning interpretations by offering complementary data analytics, cloud-based LIMS integration, or AI-driven quality controls to enhance their existing immunoassay workflow.

Regulatory Readiness Capitalize on their GMP, FDA, USDA, and ISO 13485:2016 certifications by proposing compliant manufacturing inputs, validation services, or supply chain solutions that streamline scale-up for new assays.

Growth Partnerships Position as a strategic supplier or collaborator for contract development and manufacturing services to support InBios’ expansion into emergent infectious disease tests and potential government or defense-related contracts.